We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New COVID-19 Test Detects Cell Mediated (T Cell) Immune Response to SARS-CoV-2 Infection

By HospiMedica International staff writers
Posted on 08 Mar 2021
Print article
Image: T-SPOT.COVID test (Photo courtesy of Oxford Immunotec Global PLC)
Image: T-SPOT.COVID test (Photo courtesy of Oxford Immunotec Global PLC)
A new COVID-19 test for the qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood has just been launched.

Oxford Immunotec Global PLC (Oxford, UK) has launched the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company developed the T-SPOT.COVID test as an evolution of its T-SPOT Discovery SARS-CoV-2 assay, a research use only test used to gain insights about the immune response to SARS-CoV-2. Oxford Immunotec has filed an EUA request to the FDA for the test.

Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infection. Antibodies are not always produced in response to SARS-CoV-2 infection, or may be delayed. Antibodies can also wane quickly after infection and reports show T cells may be more long lived than the antibody response. In the absence of an antibody response, the T cell response may be protective from SARS-CoV-2 infection.

In a clinical study using samples collected in the US, the T-SPOT.COVID test was proven to detect a SARS-CoV-2 cell mediated (T cell) immune response in PCR positive individuals, even with negative serology test results6. The T-SPOT.COVID test therefore, complements results obtained by antibody serology to give a more comprehensive view of an individual's adaptive immune response to SARS-CoV-2 infection. The test could also be used, for example, alongside serology tests to support clinical assessment of individuals who present with suspected COVID-19 but are PCR negative.

In the study, the T-SPOT.COVID test had a positive agreement with PCR-results of 96.6% (84/87) in SARS-CoV-2 infected individuals <60 days after first PCR positive result. At >60 days (with the furthest time point after first positive PCR test result being >240 days) positive agreement remained high at 83.3% (40/48). The T-SPOT.COVID test detected substantially more people with previous positive PCR results than serology in the cohort, whose positivity rate was lower and declined faster over time.

In an endemic cohort of US individuals selected to be at a relative lower risk of SARS-CoV-2 infection (based on the absence of self-reported symptoms, negative serology results and no prior history of a positive PCR test result for SARS-CoV-2) the T-SPOT.COVID test had a negative agreement of 98.0% (96/98). However, there is a possibility that a proportion of this group had, or still have, an asymptomatic infection, seronegative at the time of testing, but in whom the T-SPOT.COVID test was able to detect a T cell response.

"T cells and antibodies are two arms of the adaptive immune response. The detection and measurement of each can provide different insights about disease activity and an individual's personal immunity," said Phill Keefe, Senior VP, Product Design, Development and Delivery at Oxford Immunotec.

"The T-SPOT® Technology platform is a standardized way of measuring T cells. It has been proven in clinical use for over 18 years with another major infectious disease, tuberculosis, which kills around 1.5 million people every year," said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. "Our T-SPOT.COVID test is tailored specifically for the detection and measurement of an individual's T cell response to SARS-CoV-2 infection. Having the ability to determine an individual's immune response to SARS-CoV-2 has the potential to support a wide range of needs in our battle against the COVID-19 pandemic."

Related Links:
Oxford Immunotec Global PLC

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Blood and Infusion Warmer
SW300
New
Documentation System For Blood Banks
HettInfo II

Print article
Radcal

Channels

Critical Care

view channel
mage: The electroceutical epidermal patch is designed to inhibit bacterial growth (Photo courtesy of Saehyun Kim/University of Chicago)

Cutting-Edge Bioelectronic Device Offers Drug-Free Approach to Managing Bacterial Infections

Antibiotic-resistant infections pose an increasing threat to patient safety and healthcare systems worldwide. Recent estimates indicate that drug-resistant infections may rise by 70% by 2050, highlighting... Read more

Surgical Techniques

view channel
Image: Conceptual schematic showing microgrippers (µ-grippers) operating as biopsy tools in the upper urinary tract (Photo courtesy of Wangqu Liu, Yan Wan/Gracias Lab, Johns Hopkins University)

Microgrippers For Miniature Biopsies to Create New Cancer Diagnostic Screening Paradigm

The standard diagnosis of upper urinary tract cancers typically involves the removal of suspicious tissue using forceps, a procedure that is technically challenging and samples only a single region of the organ.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more